miR-34 – a microRNA replacement therapy is headed to the clinic

By A. Bader. Front. Gene., 2012

721 citations recorded by the source corpus.

MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/c3f16b0eea513769b94f6392bb69dd5615edac89

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Scott M. Hammond
2. A. Bader
3. Heidi J. Peltier
4. Frank J. Slack

In Molecular Biology

1. Scott M. Hammond
2. A. Bader
3. Heidi J. Peltier
4. Frank J. Slack

Citations in the corpus

• An overview of microRNAs (2015, background): “under development are miR-34 for cancer (Phase I) and pre-clinical therapeutics including let-7 for cancer and miR-29 for fibrosis[237, 238].”
• Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours (2020, background): “…Shin9, Carlos R. Becerra10, Gerald Falchook11, Jay Stoudemire12, Desiree Martin12, Kevin Kelnar12, Heidi Peltier12, Vinicius Bonato12, Andreas G. Bader12, Susan Smith12, Sinil Kim12, Vincent O’Neill12 and Muhammad S. Beg13 BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based…”